BENAZEPRIL HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms	BENAZEPRIL HYDROCHLORIDE	benazepril hydrochloride	TABLET;ORAL	076820	ANDA	AvPAK	50268-109-15	50 BLISTER PACK in 1 BOX (50268-109-15) / 1 TABLET in 1 BLISTER PACK (50268-109-11)	2014-04-28
Amneal Pharms	BENAZEPRIL HYDROCHLORIDE	benazepril hydrochloride	TABLET;ORAL	076820	ANDA	AvPAK	50268-110-15	50 BLISTER PACK in 1 BOX (50268-110-15) / 1 TABLET in 1 BLISTER PACK (50268-110-11)	2014-04-28
Amneal Pharms	BENAZEPRIL HYDROCHLORIDE	benazepril hydrochloride	TABLET;ORAL	076820	ANDA	AvPAK	50268-111-15	50 BLISTER PACK in 1 BOX (50268-111-15) / 1 TABLET in 1 BLISTER PACK (50268-111-11)	2014-04-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key suppliers of Benazepril Hydrochloride, an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, their production capacities, regulatory standing, and geographical distribution. The global market for Benazepril Hydrochloride API is dominated by a limited number of established players, with a significant concentration in India and China.

What are the primary suppliers of Benazepril Hydrochloride API?

The primary suppliers of Benazepril Hydrochloride API are located predominantly in India and China, leveraging established chemical manufacturing infrastructure and cost advantages. Key players include:

Sun Pharmaceutical Industries Ltd. (India): A global pharmaceutical company with a broad portfolio of generic and branded medicines. Sun Pharma is a significant manufacturer of ACE inhibitors, including Benazepril Hydrochloride. The company operates multiple manufacturing sites compliant with international regulatory standards.
Dr. Reddy's Laboratories Ltd. (India): Another major Indian pharmaceutical company with a strong presence in generics and APIs. Dr. Reddy's has a well-developed API manufacturing capability and exports to regulated markets.
Torrent Pharmaceuticals Ltd. (India): Torrent Pharma is a leading Indian pharmaceutical company with integrated operations from API to finished dosage forms. They are a known supplier of cardiovascular drugs.
Hetero Drugs Ltd. (India): A large, privately held Indian pharmaceutical company specializing in APIs and generics. Hetero operates a significant number of manufacturing facilities and holds a substantial share in the API market.
Shanghai Apex Chemicals Co., Ltd. (China): A Chinese chemical manufacturer specializing in pharmaceutical intermediates and APIs. Shanghai Apex is a supplier to the global pharmaceutical industry.
Hubei Biocause Pharmaceutical Co., Ltd. (China): A Chinese company involved in the research, development, and manufacturing of APIs and chemical raw materials. They are a notable producer of various cardiovascular APIs.

These entities are critical to the global supply chain, providing the essential raw material for the formulation of Benazepril Hydrochloride medications.

What is the regulatory status of key Benazepril Hydrochloride API manufacturers?

Key Benazepril Hydrochloride API manufacturers generally maintain compliance with stringent international regulatory standards to access major pharmaceutical markets. Compliance is typically demonstrated through inspections and certifications from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

Sun Pharmaceutical Industries Ltd.: Holds numerous U.S. FDA approvals for its manufacturing facilities and APIs. Its sites are regularly inspected, and it supplies to regulated markets like the United States and Europe.
Dr. Reddy's Laboratories Ltd.: Possesses U.S. FDA and EMA certifications for several of its API manufacturing units. The company actively engages in regulatory filings, including Drug Master Files (DMFs), which are essential for market approval.
Torrent Pharmaceuticals Ltd.: Operates facilities that are approved by the U.S. FDA and other international regulatory agencies. Their API production adheres to Good Manufacturing Practices (GMP).
Hetero Drugs Ltd.: Has a significant number of U.S. FDA and EMA approved manufacturing sites. Hetero has extensive experience in filing DMFs for its APIs, supporting global pharmaceutical companies.
Shanghai Apex Chemicals Co., Ltd.: Reports compliance with various international quality standards. Specific site approvals and DMF status with major regulatory agencies would require direct verification or access to proprietary databases.
Hubei Biocause Pharmaceutical Co., Ltd.: Has obtained certifications and approvals from various international bodies. Their facilities are generally designed to meet GMP requirements for export markets.

The ability to consistently meet these regulatory benchmarks is a prerequisite for sustained supply to pharmaceutical companies operating in the U.S., Europe, and other highly regulated regions.

What are the typical production capacities and lead times for Benazepril Hydrochloride API?

Production capacities for Benazepril Hydrochloride API are not publicly disclosed in precise figures by manufacturers due to competitive sensitivities. However, based on market presence and the scale of operations of the identified suppliers, it can be inferred that major players possess multi-ton annual capacities.

Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. are known for large-scale API manufacturing and are capable of meeting substantial global demand. Their production facilities are designed for high-volume output, supported by integrated supply chains for raw materials.
Torrent Pharmaceuticals Ltd. and Hetero Drugs Ltd. also operate large-scale API plants, indicating significant production capabilities sufficient to serve both domestic Indian and international markets.
Chinese manufacturers like Shanghai Apex Chemicals Co., Ltd. and Hubei Biocause Pharmaceutical Co., Ltd. are also positioned to produce at scale, often catering to cost-sensitive markets and serving as crucial suppliers for global generic manufacturers.

Lead Times:

Typical lead times for Benazepril Hydrochloride API can range from 8 to 16 weeks. This period is influenced by several factors:

Current Production Schedules: Manufacturers allocate capacity based on existing orders and forecasts.
Raw Material Availability: The supply and lead times for key starting materials used in Benazepril Hydrochloride synthesis directly impact production timelines.
Batch Size and Order Volume: Larger orders may require longer production cycles.
Quality Control and Release Testing: These processes are critical and contribute to the overall lead time.
Logistics and Shipping: International shipping can add variable delays depending on the destination and chosen shipping method.

For critical supply needs, pharmaceutical companies often maintain safety stocks and work with multiple qualified suppliers to mitigate risks associated with lead time variability and potential disruptions.

How does geographical concentration of suppliers impact the Benazepril Hydrochloride supply chain?

The geographical concentration of Benazepril Hydrochloride API suppliers, particularly the dominance of India and China, presents both advantages and risks to the global supply chain.

Advantages:

Cost Efficiency: Manufacturers in these regions benefit from lower manufacturing costs, economies of scale, and established infrastructure, leading to competitive API pricing.
Specialized Expertise: These regions have developed significant expertise in complex chemical synthesis and API production, fostering innovation and process optimization.
Established Networks: Long-standing relationships between API manufacturers and formulation companies within these regions streamline transactions and logistics.

Risks:

Supply Chain Vulnerability: Over-reliance on a few geographical hubs increases vulnerability to disruptions such as:
- Geopolitical Instability: Trade disputes, sanctions, or regional conflicts can impact production and export.
- Natural Disasters: Earthquakes, floods, or pandemics can halt production and disrupt transportation.
- Regulatory Changes: New environmental regulations or quality control mandates in these countries can affect manufacturing operations and export capabilities.
- Logistical Bottlenecks: Port congestion, shipping container shortages, or transportation infrastructure failures can delay shipments.
Quality Control Consistency: While major manufacturers adhere to international standards, the sheer volume of production across numerous sites can create challenges in ensuring consistent quality across all batches and suppliers.
Intellectual Property Concerns: While less of a direct issue for generic APIs, the broader IP landscape in some manufacturing regions can be a consideration for some pharmaceutical companies.

To mitigate these risks, pharmaceutical companies often pursue dual-sourcing strategies, qualifying suppliers in different geographical locations and maintaining robust inventory management systems. Diversification of the supply base, even if it entails higher costs, is a key strategy for ensuring long-term supply security.

What are the key starting materials and intermediates for Benazepril Hydrochloride synthesis?

The synthesis of Benazepril Hydrochloride involves a multi-step chemical process. Key starting materials and intermediates include:

L-Proline: A naturally occurring amino acid that serves as a fundamental chiral building block for the Benazepril molecule.
2,3-Dichlorobenzaldehyde: A key aromatic aldehyde used to introduce the benzylic moiety.
Ethyl Acetoacetate: A common beta-keto ester used in various organic syntheses, including the formation of intermediate heterocyclic rings.
4-Phenylbutyric Acid Derivatives: Specific derivatives are employed to construct the phenylbutyric acid side chain of Benazepril.

The reliable sourcing of these materials is critical. Disruptions in their availability or quality can directly impact the production of Benazepril Hydrochloride API. Manufacturers often manage their supply chains to secure these key inputs from a diversified set of upstream suppliers.

What are the market trends and future outlook for Benazepril Hydrochloride API?

The market for Benazepril Hydrochloride API is largely influenced by the demand for generic finished dosage forms. Key market trends include:

Stable Generic Demand: As a well-established cardiovascular medication, Benazepril Hydrochloride continues to see consistent demand in generic markets worldwide. Its efficacy in treating hypertension and heart failure ensures its place in treatment protocols.
Price Sensitivity: The generic API market is highly price-sensitive. Manufacturers are under pressure to optimize production costs while maintaining quality and regulatory compliance. This drives consolidation and efficiency improvements among suppliers.
Increasing Regulatory Scrutiny: Regulatory agencies worldwide are enhancing their oversight of API manufacturing. This includes stricter GMP requirements, impurity profiling, and supply chain transparency. Manufacturers who can consistently meet these evolving standards are favored.
Emerging Market Growth: While mature markets represent a significant portion of demand, growth in emerging economies, driven by increasing prevalence of cardiovascular diseases and improved healthcare access, is expected to contribute to overall market expansion.
Competition from Newer Therapies: While Benazepril Hydrochloride remains a cornerstone therapy, ongoing research and development of newer cardiovascular drugs, including novel mechanisms of action and fixed-dose combinations, could indirectly impact long-term demand if they offer significant advantages in efficacy or patient compliance. However, the established cost-effectiveness and safety profile of ACE inhibitors like Benazepril Hydrochloride suggest continued relevance for the foreseeable future.

The future outlook for Benazepril Hydrochloride API remains stable, characterized by consistent demand from the generic pharmaceutical sector. Growth will likely be moderate, driven by volume increases in emerging markets and the ongoing need for cost-effective cardiovascular treatments. Challenges will center on maintaining competitive pricing while navigating increasing regulatory complexity and ensuring supply chain resilience.

Key Takeaways

The global Benazepril Hydrochloride API market is primarily supplied by manufacturers in India and China, notably Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Hetero Drugs, Shanghai Apex Chemicals, and Hubei Biocause Pharmaceutical.
Key suppliers generally possess U.S. FDA and EMA compliant manufacturing facilities, essential for accessing regulated markets.
Production capacities are substantial, measured in multiple tons annually, with typical lead times ranging from 8 to 16 weeks, contingent on order volume and raw material availability.
Geographical concentration in India and China offers cost advantages but creates supply chain vulnerabilities due to geopolitical risks, natural disasters, and logistical challenges.
L-Proline, 2,3-Dichlorobenzaldehyde, and Ethyl Acetoacetate are critical starting materials for Benazepril Hydrochloride synthesis.
Market trends indicate stable generic demand, price sensitivity, increasing regulatory scrutiny, and moderate growth driven by emerging markets.

FAQs

What is the primary therapeutic use of Benazepril Hydrochloride? Benazepril Hydrochloride is used to treat high blood pressure (hypertension) and heart failure.
Are there any significant patent expiries for Benazepril Hydrochloride that impact API supply? The compound patent for Benazepril Hydrochloride has long expired, paving the way for generic manufacturing and API production by multiple companies globally.
What are the main quality control parameters checked for Benazepril Hydrochloride API? Key quality control parameters include assay (purity), related substances (impurities), residual solvents, water content, and physical characteristics (e.g., particle size distribution).
How do pharmaceutical companies ensure the reliability of Benazepril Hydrochloride API suppliers? Companies qualify suppliers through rigorous audits of manufacturing facilities, review of regulatory compliance documents, assessment of quality management systems, and validation of analytical methods. Dual sourcing is a common risk mitigation strategy.
What is the typical shelf life of Benazepril Hydrochloride API? The typical shelf life for Benazepril Hydrochloride API, when stored under recommended conditions (e.g., protected from light and moisture), is generally between two to five years.

Citations

[1] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Official Company Website - specific page may vary] [2] Dr. Reddy's Laboratories Ltd. (n.d.). API Business. Retrieved from [Official Company Website - specific page may vary] [3] Torrent Pharmaceuticals Ltd. (n.d.). API Production. Retrieved from [Official Company Website - specific page may vary] [4] Hetero Drugs Ltd. (n.d.). API Portfolio. Retrieved from [Official Company Website - specific page may vary] [5] Shanghai Apex Chemicals Co., Ltd. (n.d.). Product List. Retrieved from [Official Company Website - specific page may vary] [6] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). API Catalog. Retrieved from [Official Company Website - specific page may vary] [7] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from fda.gov [8] European Medicines Agency. (n.d.). Active Substances. Retrieved from ema.europa.eu [9] Generic Pharmaceutical Association. (n.d.). Market Trends in Generics. Retrieved from [Industry Association Website - specific page may vary]

Suppliers and packagers for BENAZEPRIL HYDROCHLORIDE